Prime Medicine, Inc. SEC filings document the biotechnology company's financial results, pipeline disclosures, governance matters and material events tied to its Prime Editing programs. Recent Form 8-K filings include Item 2.02 results releases, Regulation FD corporate presentations and Item 5.02 executive appointment disclosures, with exhibits summarizing business highlights for PM577 in Wilson Disease, PM647 in Alpha-1 Antitrypsin Deficiency and PM359 in chronic granulomatous disease.
Proxy materials disclose annual meeting matters, director elections, auditor ratification, executive compensation and equity-plan information. Together, the filings provide formal records of PRME's public-company governance, disclosure controls, capital and compensation arrangements, and regulatory-development communications for its genetic-medicine pipeline.
Prime Medicine, Inc. (PRME) – Form 4 insider transaction
Director and 10% owner David R. Liu disclosed the purchase of 21,000 shares of Prime Medicine common stock on 23-Jun-2025. The trade was executed under a previously adopted Rule 10b5-1 plan dated 3-Mar-2025, indicating it was pre-scheduled rather than opportunistic.
The weighted-average purchase price was $2.162 per share, with individual trades occurring between $2.06 – $2.25. Following the transaction, Liu’s direct ownership increased to 20,219,945 shares, an incremental addition of roughly 0.10 % to his existing stake.
No derivative securities were reported, and no sales occurred. While the absolute dollar value of the purchase (~$45,400) is modest relative to Liu’s overall holding, insider buying—especially by a high-ownership director—can be interpreted as a vote of confidence in the company’s prospects at current price levels.